These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 38844941)
1. Risk of recurrent venous thromboembolism and major bleeding according to risk factor profiles in Asian patients: a subgroup analysis EINSTEIN-Extension and EINSTEIN-CHOICE. Yamada N; Fu W; Shi Z; Park KH; Kim HS; Dai X; Lensing AW; Pap AF; Kohno T; Tajima T; Watakabe T; Mitsumori T Thromb J; 2024 Jun; 22(1):48. PubMed ID: 38844941 [TBL] [Abstract][Full Text] [Related]
2. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Prins MH; Lensing AWA; Prandoni P; Wells PS; Verhamme P; Beyer-Westendorf J; Bauersachs R; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Kakkar AK; van Bellen B; Pap AF; Homering M; Tamm M; Weitz JI Blood Adv; 2018 Apr; 2(7):788-796. PubMed ID: 29632234 [TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. Imberti D; Pomero F; Mastroiacovo D Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579 [TBL] [Abstract][Full Text] [Related]
4. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. Robertson L; Yeoh SE; Ramli A Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199 [TBL] [Abstract][Full Text] [Related]
5. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Prandoni P; Lensing AWA; Prins MH; Gebel M; Pap AF; Homering M; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Cohen AT; Davidson BL; van Bellen B; Verhamme P; Wells PS; Yuan Z; Levitan B; Weitz JI Thromb Res; 2018 Aug; 168():121-129. PubMed ID: 30064683 [TBL] [Abstract][Full Text] [Related]
6. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Weitz JI; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Holberg G; Kakkar A; Lensing AW; Prins M; Haskell L; van Bellen B; Verhamme P; Wells PS; Prandoni P; Thromb Haemost; 2015 Aug; 114(3):645-50. PubMed ID: 25994838 [TBL] [Abstract][Full Text] [Related]
8. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Wells PS; Gebel M; Prins MH; Davidson BL; Lensing AW Thromb J; 2014; 12():26. PubMed ID: 25698905 [TBL] [Abstract][Full Text] [Related]
9. Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J; Baker WL Am J Med; 2019 Apr; 132(4):498-504. PubMed ID: 30582894 [TBL] [Abstract][Full Text] [Related]
10. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis. Djulbegovic M; Lee AI; Chen K J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project. Bortoluzzi C; Bernardi E; Camporese G; Noventa F; Ceccato D; Tonello C; Vo Hong N; Campello E; Simion C; Imbalzano E; Di Micco P; Callegari E; Simioni P Life (Basel); 2022 Oct; 12(10):. PubMed ID: 36295091 [TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban and the EINSTEIN clinical trial programme. Cohen AT; Bauersachs R Blood Coagul Fibrinolysis; 2019 Apr; 30(3):85-95. PubMed ID: 30920394 [TBL] [Abstract][Full Text] [Related]
13. Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. Weitz JI; Chan NC Thromb Haemost; 2019 May; 119(5):689-694. PubMed ID: 30808045 [TBL] [Abstract][Full Text] [Related]
14. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). Marshall A; Levine M; Hill C; Hale D; Thirlwall J; Wilkie V; French K; Kakkar A; Lokare A; Maraveyas A; Chapman O; Arif A; Petrou S; Maredza M; Hobbs R; Dunn JA; Young AM J Thromb Haemost; 2020 Apr; 18(4):905-915. PubMed ID: 31995662 [TBL] [Abstract][Full Text] [Related]
15. [EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism]. Kaymaz C Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):1-7. PubMed ID: 28947723 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study. Coleman CI; Peacock WF; Bunz TJ; Beyer-Westendorf J Thromb Res; 2018 Aug; 168():31-36. PubMed ID: 29883907 [TBL] [Abstract][Full Text] [Related]
17. Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Schindewolf M; Weitz JI Thromb Haemost; 2020 Jan; 120(1):14-26. PubMed ID: 31858522 [TBL] [Abstract][Full Text] [Related]
19. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. Berger JS; Seheult R; Laliberté F; Crivera C; Lejeune D; Xiao Y; Schein J; Lefebvre P; Kaatz S Res Pract Thromb Haemost; 2018 Jan; 2(1):58-68. PubMed ID: 30046707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]